The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Self-citationAnti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Self-citationUmaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Self-citationYamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Humanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R., Frantz, K. K., Peele, C. G., Black, A., Passmore, D., Moldovan-Loomis, C., Srinivasan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1260 · Cited by 421
Macher, B. A., & Galili, U. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.11.003 · Cited by 404
Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life
Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 402
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
The Structure of a Human Type III Fcγ Receptor in Complex with Fc
Radaev, S., Motyka, S., Fridman, W.-H., Sautes-Fridman, C., & Sun, P. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100350200 · Cited by 354
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Self-citationQian, J., Liu, T., Yang, L., Daus, A., Crowley, R., & Zhou, Q. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.023 · Cited by 291
Simmons, L. C., Reilly, D., Klimowski, L., Shantha Raju, T., Meng, G., Sims, P., Hong, K., Shields, R. L., Damico, L. A., Rancatore, P., et al. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00036-4 · Cited by 282
Human Antibody Effector Function
Burton, D. R., & Woof, J. M. (1992) · Advances in Immunology · doi:10.1016/s0065-2776(08)60486-1 · Cited by 265
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Niwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.08.009 · Cited by 244
Bitonti, A. J., Dumont, J. A., Low, S. C., Peters, R. T., Kropp, K. E., Palombella, V. J., Stattel, J. M., Lu, Y., Tan, C. A., Song, J. J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403235101 · Cited by 233
Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Wacker, M., Feldman, M. F., Callewaert, N., Kowarik, M., Clarke, B. R., Pohl, N. L., Hernandez, M., Vines, E. D., Valvano, M. A., Whitfield, C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509207103 · Cited by 194
Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
Schmiedel, J., Blaukat, A., Li, S., Knöchel, T., & Ferguson, K. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.019 · Cited by 154
Heterogeneity of recombinant antibodies: linking structure to function.
Harris, R. (2005) · PubMed · Cited by 141
Jones, A. J. S., Papac, D. I., Chin, E. H., Keck, R. G., Baughman, S. A., Lin, Y. S., Kneer, J., & Battersby, J. E. (2007) · Glycobiology · doi:10.1093/glycob/cwm017 · Cited by 137
Campylobacter sugars sticking out
Guerry, P., & Szymanski, C. M. (2008) · Trends in Microbiology · doi:10.1016/j.tim.2008.07.002 · Cited by 128
Shibata‐Koyama, M., Iida, S., Okazaki, A., Mori, K., Kitajima-Miyama, K., Saitou, S., Kakita, S., Kanda, Y., Shitara, K., Kato, K., et al. (2008) · Glycobiology · doi:10.1093/glycob/cwn110 · Cited by 117
Human IgG2 Antibody Disulfide Rearrangement in Vivo
Liu, D., Chen, X., Enk, J. Z.-V., Plant, M., Dillon, T. M., & Flynn, G. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804787200 · Cited by 116
Suzuki, E., Niwa, R., Saji, S., Muta, M., Hirose, M., Iida, S., Shiotsu, Y., Satoh, M., Shitara, K., Kondo, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1335 · Cited by 111
Ghirlando, R., Lund, J., Goodall, M. D., & Jefferis, R. (1999) · Immunology Letters · doi:10.1016/s0165-2478(99)00029-2 · Cited by 107
Self-citationKaragiannis, P., Singer, J., Hunt, J., Gan, S. K., Rudman, S. M., Mechtcheriakova, D., Knittelfelder, R., Daniels‐Wells, T. R., Hobson, P. S., Beavil, A. J., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0607-1 · Cited by 106
Complement and cellular cytotoxicity in antibody therapy of cancer
Wang, S., & Weiner, G. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.759 · Cited by 102
HOLLAND, M., Hewins, P., Goodall, M. D., Adu, D., Jefferis, R., & Savage, C. O. S. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02566.x · Cited by 97
Self-citationEffector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor
Dechant, M., Beyer, T. D., Schneider‐Merck, T., Weisner, W., Peipp, M., van de Winkel, J. G. J., & Valerius, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2936 · Cited by 96
Interactions of Immunoglobulins Outside the Antigen-Combining Site
Nezlin, R. S., & Ghetie, V. F. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)82004-2 · Cited by 76
Keck, R. G., Nayak, N., Lerner, L. E., Raju, S., Ma, S., Schreitmueller, T., Chamow, S., Moorhouse, K., Kotts, C. E., & Jones, A. J. S. (2007) · Biologicals · doi:10.1016/j.biologicals.2007.05.004 · Cited by 72
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 72
Antibody-Based Therapy for Solid Tumors
Li, Y., Hsu, K., & Beckman, R. A. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d71a · Cited by 71
Nechansky, A., Schuster, M., Jost, W. H., Siegl, P., Wiederkum, S., Gorr, G., & Kircheis, R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.08.013 · Cited by 70
Glycosylation and Placental Transport of Immunoglobulin G.
KIBE, T., FUJIMOTO, S., ISHIDA, C., TOGARI, H., WADA, Y., OKADA, S., NAKAGAWA, H., TSUKAMOTO, Y., & TAKAHASHI, N. (1996) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.21.57 · Cited by 63
Melmed, G., Targan, S., Yasothan, U., Hanicq, D., & Kirkpatrick, P. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2654 · Cited by 63
Ashford, D. A., Alafi, C. D., Gamble, V., Mackay, D., Rademacher, T. W., Williams, P., Dwek, R. A., Barclay, A. N., Davis, S. J., & Somoza, C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53687-5 · Cited by 57
Effector mechanisms of therapeutic antibodies against ErbB receptors
Peipp, M., Dechant, M., & Valerius, T. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.012 · Cited by 48
Congy‐Jolivet, N., Probst, A., Watier, H., & Thibault, G. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.013 · Cited by 37
Meeting report & News from academia
Moutel, S., & Perez, F. (2008) · Biotechnology Journal · doi:10.1002/biot.200800011 · Cited by 9
Cited by
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Metadata
- Authors
- Jefferis, R.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 30
- Issue
- 7
- Pages
- 356-362
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2072086606
- Cited by
- 330
- References
- 56
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.